| Aug 27 |
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
|
| Aug 22 |
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
|
| Aug 16 |
CNS Pharmaceuticals reports Q2 results
|
| Aug 15 |
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
|
| Jul 30 |
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
|
| Jul 25 |
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
|
| Jul 16 |
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
|
| Jul 12 |
CNS Pharmaceutical files for 2.36M offering of common stock
|
| Jul 3 |
CNS Pharmaceuticals announces pricing of registered direct offering and concurrent private placement
|
| Jun 26 |
CNS Pharmaceuticals stock falls on pricing of direct offering
|
